AbbVie Inc.
For the period ended Dec 31, 2025. Filed Feb 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 20, 2026
ABBV$293.89+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income
| years ended December 31 (in millions) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net earnings | $4,233 | $4,286 | $4,873 |
| Foreign currency translation adjustments, net of tax expense (benefit) of $63 in 2025, $(39) in 2024 and $15 in 2023 | 1,481 | (1,008) | 407 |
| Net investment hedging activities, net of tax expense (benefit) of $(266) in 2025, $133 in 2024 and $(109) in 2023 | (971) | 484 | (399) |
| Pension and post-employment benefits, net of tax expense (benefit) of $98 in 2025, $206 in 2024 and $(6) in 2023 | 421 | 824 | (30) |
| Cash flow hedging activities, net of tax expense (benefit) of $(18) in 2025, $16 in 2024 and $(19) in 2023 | (150) | 80 | (84) |
| Other comprehensive income (loss) | $781 | $380 | $(106) |
| Comprehensive income | 5,014 | 4,666 | 4,767 |
| Comprehensive income attributable to noncontrolling interest | 7 | 8 | 10 |
| Comprehensive income attributable to AbbVie Inc. | $5,007 | $4,658 | $4,757 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.